LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.


Arecor Therapeutics Plc

-5.00 (-1.96%)
Share Name Share Symbol Market Type Share ISIN Share Description
Arecor Therapeutics Plc LSE:AREC London Ordinary Share GB00BMWLM973 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  -5.00 -1.96% 250.00 1,039 11:00:26
Bid Price Offer Price High Price Low Price Open Price
240.00 260.00 255.00 250.00 255.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Coml Physical, Biologcl Resh 3.54 -9.26 - - 76.55
Last Trade Time Trade Type Trade Size Trade Price Currency
16:26:42 O 1,000 250.00 GBX

Arecor Therapeutics (AREC) Latest News

Arecor Therapeutics (AREC) Discussions and Chat

Arecor Therapeutics Forums and Chat

Date Time Title Posts

Add a New Thread

Arecor Therapeutics (AREC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-06-01 15:26:43250.001,0002,500.00O
2023-06-01 13:56:06251.503998.09O

Arecor Therapeutics (AREC) Top Chat Posts

Top Posts
Posted at 21/3/2023 16:55 by sharesoc
In case you missed our webinar with Arecor Therapeutics plc (AREC) earlier this month, the recording can be found on our YouTube channel: hTTps://
Posted at 12/3/2023 10:14 by stupidboypike
Tipped by Midas:-

Best regards SBP

Posted at 24/2/2023 22:01 by sharesoc
ShareSoc is hosting a webinar with Arecor Therapeutics plc (AREC) on 07 March 2023, which may be of interest to current shareholders or potential investors. Sarah Howell Ph.D (Chief Executive Officer) and Susan Lowther (Chief Financial Officer) will be presenting. You can register here: hTTps://
Posted at 12/10/2022 09:13 by stupidboypike
This tweet looks positive enough:-

However, I must confess I was a little disappointed that AT247 did not demonstrate statistically significant glucose lowering compared to Fiasp.

I noted this comment in the RNS:-
"We look forward to analysing the data in detail and defining our future clinical development plan."

So it looks to me as if there is more work to do on AT247 to see if it can improve its glucose lowering effect.

We still have the trial of AT278 to look forward to, starting this quarter, but I think an effective AT247, will be a while away.

Interesting that there was no share price movement on this news, I guess the markets were not pricing in a complete success. I remain (very) invested in this share for the medium to long term.

Best regards SBP

Posted at 01/8/2022 16:13 by stupidboypike
Glad you got some timbo, I've been looking at the deal for a while now and I do think on balance it looks very good news. I'm already very overweight in Arecor, so I haven't taken any in this round, although I think 300p with EIS relief is a very good price.
Best regards SBP

Posted at 01/8/2022 15:59 by timbo003
I managed to pick up a few (EIS) shares in the Book build, but was scaled back by 64%, however given that the share register for Arecor reads like a who's who in the VCT world and VCTs had another bumper fund raising year last tax year, I was expecting a larger scale back than that.
Posted at 01/8/2022 09:24 by stupidboypike
Interestingly I remember hearing that the glucagon development had been put on hold as another company was making good progress with it. I guess that is this one. This could be a very smart move by Arecor. Not thrilled about the dilution, but if they have got it right that will be a very sensible price to pay I think. I also like the fact that half the payment is not due until/unless the acquired company becomes profitable.

Best regards SBP

Posted at 01/8/2022 07:55 by 18bt
First reaction: looks highly complementary. However placing is c10% increase in share capital, but they are targeting a v small discount albeit to a share price which has reduced a lot in last couple of weeks. Potentially large deferred consideration which will have to be watched.
Posted at 06/4/2022 08:45 by stupidboypike
sn, I agree, in fact we can see what happened in September when some people did want to buy in quantity, the share price doubled in a very short period. I have a decent holding of Arecor, built up over many years ( I held from the formation of the company), and I don't intend selling any until the value has properly started to come out. That in my opinion is many times the current market cap.

Best regards SBP

Posted at 23/3/2022 07:38 by alloa2003
Nice progress:-


Further strengthens the Company's extensive patent portfolio protecting its proprietary Arestat™ technology and diabetes product portfolio

Cambridge, UK, 23 March 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, is pleased to announce that the United States Patent and Trademark Office has granted a patent (US11278624) protecting novel formulations of the Group's proprietary insulin products, AT247 and AT278.

Dr Jan Jezek, Chief Scientific Officer at Arecor, commented: "Arecor's novel insulin products, based on a combination of existing insulin analogues and our highly innovative formulation science, have potential to improve convenience, compliance and enable more effective management of blood glucose for people living with type 1 and type 2 diabetes. As the clinical validation of the superiority of these products compared to current gold standard prandial insulins continues, we are also advancing the intellectual property protection for these products. This recently granted US patent, the first within the Group's comprehensive insulin IP strategy, is a significant milestone, and we will continue to strengthen our IP portfolio with additional patent applications already in progress."

Arecor has invested in building a strong patent portfolio to protect the Arestat™ technology platform and its proprietary pipeline products. The Group's intellectual property (IP) portfolio currently comprises 36 patent families, including >50 granted patents in Europe, the US and in other key territories. As part of this strategy, Arecor has robust IP directed to the novel insulin compositions that protect different aspects of AT247 and AT278 formulations, as well as their specific properties and methods of use. Arecor's strategy is to generate a fortress of both narrow and broad interrelated IP rights that cover the features of these products. US11278624 is the first granted US patent within the Group's comprehensive insulin IP strategy.

Arecor Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
Arecor The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230602 04:48:30